Treatments for fatigue in multiple sclerosis: a rapid and systematic review

P Brañas; R Jordan; A Fry-Smith; A Burls; C Hyde

Treatments for fatigue in multiple sclerosis: a rapid and systematic review

P Brañas, R Jordan, A Fry-Smith, A Burls, C Hyde

Research output: Contribution to journal › Article › peer-review

168 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is an important problem both for people with the disease and for society. There is no cure, and alleviation of symptoms forms the cornerstone of care. Excessive fatigue that severely limits activity is experienced by at least two-thirds of the estimated 60,000 people with MS in the UK.

Original language	English
Pages (from-to)	1-61
Number of pages	61
Journal	Health Technology Assessment
Volume	4
Issue number	27
Publication status	Published - 2000

Keywords

Amantadine
Central Nervous System Stimulants
Cost-Benefit Analysis
Dopamine Agents
Evidence-Based Medicine
Fatigue
Humans
Multiple Sclerosis
Pemoline

Cite this

@article{2bbfc270ad4645f8abe9b20a333f11cf,

title = "Treatments for fatigue in multiple sclerosis: a rapid and systematic review",

abstract = "Multiple sclerosis (MS) is an important problem both for people with the disease and for society. There is no cure, and alleviation of symptoms forms the cornerstone of care. Excessive fatigue that severely limits activity is experienced by at least two-thirds of the estimated 60,000 people with MS in the UK.",

keywords = "Amantadine, Central Nervous System Stimulants, Cost-Benefit Analysis, Dopamine Agents, Evidence-Based Medicine, Fatigue, Humans, Multiple Sclerosis, Pemoline",

author = "P Bra{\~n}as and R Jordan and A Fry-Smith and A Burls and C Hyde",

year = "2000",

language = "English",

volume = "4",

pages = "1--61",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "NIHR Health Technology Assessment Programme",

number = "27",

}

TY - JOUR

T1 - Treatments for fatigue in multiple sclerosis

T2 - a rapid and systematic review

AU - Brañas, P

AU - Jordan, R

AU - Fry-Smith, A

AU - Burls, A

AU - Hyde, C

PY - 2000

Y1 - 2000

N2 - Multiple sclerosis (MS) is an important problem both for people with the disease and for society. There is no cure, and alleviation of symptoms forms the cornerstone of care. Excessive fatigue that severely limits activity is experienced by at least two-thirds of the estimated 60,000 people with MS in the UK.

AB - Multiple sclerosis (MS) is an important problem both for people with the disease and for society. There is no cure, and alleviation of symptoms forms the cornerstone of care. Excessive fatigue that severely limits activity is experienced by at least two-thirds of the estimated 60,000 people with MS in the UK.

KW - Amantadine

KW - Central Nervous System Stimulants

KW - Cost-Benefit Analysis

KW - Dopamine Agents

KW - Evidence-Based Medicine

KW - Fatigue

KW - Humans

KW - Multiple Sclerosis

KW - Pemoline

M3 - Article

C2 - 11074395

SN - 1366-5278

VL - 4

SP - 1

EP - 61

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 27

ER -

Treatments for fatigue in multiple sclerosis: a rapid and systematic review

Abstract

Keywords

Fingerprint

Cite this